logo
Plus   Neg
Share
Email

AstraZeneca To Sell Commercial Rights For Losec To Cheplapharm - Quick Facts

AstraZeneca plc (AZN.L,AZN) has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm. Cheplapharm will pay AstraZeneca approximately $243 million, plus sales-contingent milestones of up to $33 million. Losec is a proton pump inhibitor discovered and developed by AstraZeneca, which helps to reduce the amount of acid produced by the stomach in patients with gastrointestinal reflux conditions and ulcers.

Separately, AstraZeneca said the US FDA has issued a complete response letter regarding the New Drug Application for PT010. The company said it will now work closely with the FDA regarding next steps, including submitting for review recent results from the second positive Phase III trial, ETHOS.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apotex Corp. recalled all lots of type 2 diabetes medication Metformin hydrochloride in the form of oral film-coated tablets for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Groupe Renault plans to cut about 14,600 jobs across the world and lower its production capacity. The plan includes almost 4,600 jobs reduction in France, through voluntary retirement and retraining. Amazon said it will convert 125,000 of the 175,000 temporary workers it hired in March amid the coronavirus pandemic, to permanent full-time employees in June. The e-commerce giant had hired the temporary employees in March to meet strong consumer demand amid the lockdown. The job openings were in Amazon's fulfillment centers and its delivery network.
Follow RTT